Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recent Biotech Financings: Viamet, Intellikine, Xenoport, Zosano

This article was originally published in The Pink Sheet Daily

Executive Summary

At least for these four companies, there are no summer doldrums in investment activity; Viamet is a notable example of increased participation by big pharma venture groups in early-stage biotech financings.
Advertisement

Related Content

Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS069715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel